News and Trends 25 Apr 2018 Cancer Treatment Targeting DNA Repair is Tested in Humans for the First Time Onxeo has initiated a Phase I trial testing its first-in-class cancer treatment that works by inhibiting the repair of tumor DNA. Onxeo, a French biotech, has dosed its first patient in a Phase I study testing its cancer treatment AsiDNA, the first treatment of its kind, for advanced solid tumors. The news follows the Phase […] April 25, 2018 - 1 minutemin - By Alexander Burik Share WhatsApp Twitter Linkedin Email
Interview 25 Apr 2018 Planting the Seeds to Grow the Italian Biotech Industry Many European countries, including the UK, France, Germany, and Switzerland, boast a thriving biotech industry. Others are still a step behind when it comes to industrializing their research. Let’s take a look at how Italy is pushing through to make it to the first league. Italy is certainly a pioneer and leader in life science research — […] April 25, 2018 - 3 minutesmins - By Editorial Team Share WhatsApp Twitter Linkedin Email
News and Trends 24 Apr 2018 Fundraising Boosts Italian Red Blood Cell Therapy EryDel has raised €26.5M to develop a red blood cell drug delivery system to treat a rare disease of the immune and nervous systems. Italian biotech EryDel has raised €26.5M to complete a Phase III trial testing a unique technology to treat ataxia telangiectasia, a rare genetic disorder. The fundraising was led by Sofinnova Partners, a leading European venture […] April 24, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 24 Apr 2018 New Class of Antibiotics Combats the Three Deadliest Bacteria in the World A new class of antibiotics developed by Polyphor has been shown to be effective against the three most dangerous drug-resistant bacteria in the world. Polyphor’s novel class of antibiotics has been shown to effectively combat the three bacteria marked as critical, priority 1 by the World Health Organization. To date, there are very limited to no […] April 24, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
In Depth 24 Apr 2018 Can DIY Biology Ever Become a Big Player in Biotech? Alongside university research and industry R&D, a third, parallel community actively uses tools and methods of the life sciences: biohackers. What are they, and what is their impact on biotech and the startup scene? One of the richest persons alive and one of the first hackers ever, Bill Gates, said that if he were young today […] April 24, 2018 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 23 Apr 2018 The First CAR-T Therapy Is Not Living Up to Commercial Expectations Novartis’ Kymriah, the first approved CAR-T therapy worldwide, has performed far below sales expectations in the last quarter. The news highlights the challenges CAR-T therapies still face before becoming a commercially viable treatment option. CAR-T therapy has shown impressive results treating the cancer of patients for which all other treatments fail. One would expect this […] April 23, 2018 - 3 minutesmins - By Editorial Team Share WhatsApp Twitter Linkedin Email
News and Trends 20 Apr 2018 Gene Therapy For Beta-Thalassemia Could Eliminate Need for Transfusions Bluebird bio has obtained results from two clinical studies showing its new gene therapy could eliminate the need for red blood cell transfusions in patients with beta-thalassemia. The company plans to file for an EU approval of its treatment later this year. US firm bluebird bio has results from two clinical studies showing its LentiGlobin gene […] April 20, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 19 Apr 2018 Major $115M Fundraising Fuels AI Drug Development BenevolentAI has raised a massive second round of fundraising to expand the drug developing capabilities of its artificial intelligence technology. The technology could significantly increase the speed and efficiency of the drug discovery process. BenevelontAI, based in London, has raised an impressive $115M (€93M) to advance its use of AI in drug development. The funding, raised from […] April 19, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 19 Apr 2018 “This is the First Time CAR-T Has Ever Worked on Acute Myeloid Leukemia“ Celyad has reported clinical results showing the first time a patient has fully recovered from acute myeloid leukemia thanks to a CAR-T therapy, and without the need for chemotherapy preconditioning. At the AACR meeting in Chicago this week, Celyad has presented preliminary data from three of its ongoing Phase 1 clinical trials with a new […] April 19, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 18 Apr 2018 Finnish Rapid Molecular Diagnostic Test Enters European Market Mobidiag, a Finnish biotech, has launched a diagnostic test that can rapidly detect the most common disease-causing microbes in the gut. The test can help manage infections more effectively at an earlier stage. Mobidiag has launched a molecular diagnostic test on the European market that checks patient samples for numerous bacterial targets, including the most […] April 18, 2018 - 1 minutemin - By Alexander Burik Share WhatsApp Twitter Linkedin Email
Interview 18 Apr 2018 What Lies Ahead for European Cell and Gene Therapies? Cell and gene therapies have recently made big advances in providing effective treatments for a variety of conditions, from cancers to rare diseases. Nonetheless, there are still significant challenges ahead before the technologies can become a viable treatment option for most patients. What if you could treat a disease on the level of tissue and […] April 18, 2018 - 5 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 17 Apr 2018 How Low Can the Price of a Next Generation DNA Sequencer Go? The next generation of DNA sequencers has arrived, and with it, a clash of titans: Illumina, Thermo Fisher and Qiagen are all competing for the clinical diagnostics market. Next-generation sequencing (NGS) companies are redefining DNA sequencing. What began as small-scale PCR and Sanger sequencing efforts have now mushroomed into a $20Bn market with broad medical implications for […] April 17, 2018 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email